Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eLEcTRA: Letrozole with or without Trastuzumab in metastatic breast cancer
NCT00171847Phase 4Terminated
- Sponsor
- Novartis
- Start
- Mar 2003
- Primary completion
- Oct 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trastuzumab in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Time to progression at 3 months. Started Mar 2003; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00171847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171847.